Bevacizumab gamma (neovascular age-related macular degeneration) – Benefit assessment according to §35a Social Code Book V

Report documents

1. Extract of dossier assessment

   Bevacizumab gamma (neovascular age-related macular degeneration) – Benefit assessment according to §35a Social Code Book V

   published on

   01.08.2025

   Document type

   PDF-Dokument, 327 kB, EN, PDF

   DOI-Link

   https://doi.org/10.60584/A25-57_en

   Download file : Extract of dossier assessment (PDF-Dokument, 327 kB, EN, PDF)
2. Dossier assessment

   Bevacizumab gamma (neovascular age-related macular degeneration) – Benefit assessment according to §35a Social Code Book V

   published on

   01.08.2025

   Document type

   PDF-Dokument, 559 kB, DE, PDF

   DOI-Link

   https://doi.org/10.60584/A25-57

   Download file : Dossier assessment (PDF-Dokument, 559 kB, DE, PDF)

Dossier assessment

Project details

Project no.

A25-57

Commission

Commission awarded on 30.04.2025 by the Federal Joint Committee (GBA).

Report type

Dossier assessment

Status

Commission completed

Department/Division

Drug Assessment

Topic

Head and nerves

Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A25-57